Stoke Therapeutics Inc. (STOK) exhibits 45.0% gross margins and -6.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into -11.2% operating margin and -6.1% ROIC, outpacing sector cost of capital.
ROIC: -6.1% // GM: 45.0%YoY revenue trajectory of +180.0% paired with 2.64% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +180.0% // FCF YLD: 2.64%Altman Z-Score of 14.79 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 14.79 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $26.48 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -3.7% net margins.
NET MARGIN: -3.7% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for STOK & activate live FRED threshold breach alerts.